Aldo M Roccaro

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia
    Aldo M Roccaro
    Medical Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA 02115, USA
    Blood 111:4752-63. 2008
  2. ncbi request reprint Bortezomib in the treatment of cancer
    Aldo M Roccaro
    Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy
    Recent Pat Anticancer Drug Discov 1:397-403. 2006
  3. doi request reprint Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia
    Aldo M Roccaro
    Bing Center for Waldenstrom s Macroglobulinemia, Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Clin Cancer Res 14:1849-58. 2008
  4. pmc microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia
    Aldo M Roccaro
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 113:4391-402. 2009
  5. pmc Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology
    Antonio Sacco
    Dana Farber Cancer Institute, Medical Oncology, Harvard Medical School, Boston, MA, USA
    J Hematol Oncol 3:38. 2010
  6. ncbi request reprint Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia
    A Sacco
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 02115 Boston, MA, USA
    Curr Cancer Drug Targets 11:1025-9. 2011
  7. doi request reprint Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia
    Antonio Sacco
    Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 17:1753-64. 2011
  8. pmc MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma
    Aldo M Roccaro
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Blood 113:6669-80. 2009
  9. ncbi request reprint FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance
    Hiroshi Yasui
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 65:7478-84. 2005
  10. pmc microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia
    Aldo M Roccaro
    Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 116:1506-14. 2010

Collaborators

Detail Information

Publications47

  1. pmc Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia
    Aldo M Roccaro
    Medical Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA 02115, USA
    Blood 111:4752-63. 2008
    ..Theses studies enhance our understanding of the biologic role of the proteasome pathway in WM, and provide the preclinical basis for clinical trials of combinations of proteasome inhibitors in WM...
  2. ncbi request reprint Bortezomib in the treatment of cancer
    Aldo M Roccaro
    Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy
    Recent Pat Anticancer Drug Discov 1:397-403. 2006
    ..This reviews focuses on the proteasome inhibition exerted by bortezomib, the first proteasome inhibitor to have shown anti-cancer activity in both solid and haematologic malignancies...
  3. doi request reprint Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia
    Aldo M Roccaro
    Bing Center for Waldenstrom s Macroglobulinemia, Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Clin Cancer Res 14:1849-58. 2008
    ..Whether resveratrol could inhibit proliferation or induce cytotoxicity in Waldenström's macroglobulinemia (WM) was investigated...
  4. pmc microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia
    Aldo M Roccaro
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 113:4391-402. 2009
    ..These data indicate that microRNAs play a pivotal role in the biology of WM; represent important prognostic marker; and provide the basis for the development of new microRNA-based targeted therapies in WM...
  5. pmc Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology
    Antonio Sacco
    Dana Farber Cancer Institute, Medical Oncology, Harvard Medical School, Boston, MA, USA
    J Hematol Oncol 3:38. 2010
    ..These findings provide a better understanding of the underlying molecular changes that lead to the initiation and progression of this disease...
  6. ncbi request reprint Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia
    A Sacco
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 02115 Boston, MA, USA
    Curr Cancer Drug Targets 11:1025-9. 2011
    ....
  7. doi request reprint Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia
    Antonio Sacco
    Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 17:1753-64. 2011
    ..We therefore evaluated carfilzomib, a potent selective, irreversible inhibitor of the CT-L activity of the i20S and c20S in WM cells...
  8. pmc MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma
    Aldo M Roccaro
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Blood 113:6669-80. 2009
    ..These data indicate that microRNAs play a pivotal role in the biology of MM and represent important targets for novel therapies in MM...
  9. ncbi request reprint FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance
    Hiroshi Yasui
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 65:7478-84. 2005
    ..These results suggest that FTY720 overcomes drug resistance in multiple myeloma cells and provide the rationale for its clinical evaluation to improve patient outcome in multiple myeloma...
  10. pmc microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia
    Aldo M Roccaro
    Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 116:1506-14. 2010
    ..These findings confirm that histone-modifying genes and HDAC activity are deregulated in WM cells, partially driven by the aberrant expression of miRNA-206 and -9* in the tumor clone...
  11. doi request reprint Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia
    Aldo M Roccaro
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 18:6609-22. 2012
    ..We therefore sought to dissect the mechanisms of everolimus-dependent modulation of Waldenstrom macroglobulinemia cell survival...
  12. pmc CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
    Abdel Kareem Azab
    Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 113:4341-51. 2009
    ..These experiments provide a proof of concept for the use of agents that disrupt interaction with the microenvironment for enhancement of efficacy of cytotoxic agents in cancer therapy...
  13. pmc Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia
    Aldo M Roccaro
    Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 115:4051-60. 2010
    ..These findings suggest that targeting i20S and c20S CT-L activity by ONX0912 represents a valid antitumor therapy in WM...
  14. doi request reprint Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia
    Xavier Leleu
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 113:626-34. 2009
    ..Finally, we demonstrate that ER stress inducer synergizes with other agents used in the treatment of WM. These preclinical studies provide a framework for further evaluation of ER stress inducing agents as therapeutic agents in WM...
  15. pmc Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia
    Hai T Ngo
    Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:6035-41. 2009
    ..We sought to determine whether the protein tyrosine kinase Src regulates adhesion, migration, and survival in Waldenstrom macroglobulinemia...
  16. doi request reprint FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation
    Abdel Kareem Azab
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 17:4389-99. 2011
    ..Cell cycle was performed by PI staining of cells and flow cytometry. The combinatory effect of dovitinib with other drugs was analyzed using Calcusyn software. The effect of dovitinib was tested in vivo...
  17. ncbi request reprint Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway
    Kenji Ishitsuka
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Oncogene 24:5888-96. 2005
    ....
  18. pmc Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis
    Kenji Ishitsuka
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 106:1794-800. 2005
    ..Taken together, our results provide the preclinical rationale for clinical protocols of HNK to improve patient outcome in MM...
  19. doi request reprint Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemia
    Feda Azab
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 18:91-104. 2012
    ..In this study, we characterized the role of Eph-B2 receptor in the interaction of Waldenstrom's macroglobulinemia (WM) cells with the bone marrow microenvironment...
  20. pmc P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment
    Abdel Kareem Azab
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Blood 119:1468-78. 2012
    ..These data highlight the critical contribution of PSGL-1 to the regulation of growth, dissemination, and drug resistance in MM in the context of the BM microenvironment...
  21. doi request reprint Role of proteasome inhibition in Waldenström's macroglobulinemia
    Aldo M Roccaro
    Medical Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA 02115, USA
    Clin Lymphoma Myeloma 9:94-6. 2009
    ..Among them the role of proteasome inhibitors has been widely dissected providing the preclinical basis for clinical trials of combinations of proteasome inhibitors in WM...
  22. pmc Targeting NF-kappaB in Waldenstrom macroglobulinemia
    Xavier Leleu
    Medical Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
    Blood 111:5068-77. 2008
    ..Moreover, a combination of these drugs with the CD20 monoclonal antibody rituximab further increased their cytotoxic activity. Thus, effective WM therapy may require combination regimens targeting the NF-kappaB pathway...
  23. pmc Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features
    Abdel Kareem Azab
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 119:5782-94. 2012
    ..Further studies to manipulate hypoxia to regulate tumor dissemination as a therapeutic strategy are warranted...
  24. pmc Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia
    Aldo M Roccaro
    Medical Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
    Blood 115:559-69. 2010
    ..These studies therefore show that dual targeting of the PI3K/mTOR pathway is a better modality of targeted therapy for tumors that harbor activation of the PI3K/mTOR signaling cascade, such as WM...
  25. pmc Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma
    Simona Blotta
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 120:5002-13. 2012
    ..Altogether, our data demonstrate activation of both canonical and noncanonical Hh pathway in MM, thus providing the rationale for testing Hh inhibitors in clinical trials to improve MM patient outcome...
  26. pmc BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression
    Aldo M Roccaro
    Dana Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Clin Invest 123:1542-55. 2013
    ....
  27. pmc Targeting the bone marrow in Waldenstrom macroglobulinemia
    Irene M Ghobrial
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Lymphoma Myeloma Leuk 11:S65-9. 2011
    ..These include chemokines, adhesion molecules, Src/PI3K/Akt/mTOR signaling, NF-kB activation, and micro-RNA regulation in WM. Targeting these pathways in clinical trials could lead to significant responses in this rare disease...
  28. pmc Defining the role of TORC1/2 in multiple myeloma
    Patricia Maiso
    Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 118:6860-70. 2011
    ..Dual TORC1/2 inhibition showed better inhibition of adhesion to BM microenvironmental cells and inhibition of homing in vivo. These studies form the basis for further clinical testing of TORC1/2 inhibitors in MM...
  29. doi request reprint Key role of microRNAs in Waldenström's macroglobulinemia pathogenesis
    Antonio Sacco
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Clin Lymphoma Myeloma Leuk 11:109-11. 2011
    ..It has been recently demonstrated that microRNAs may be responsible for modulating histone acetylation in WM cells, thus providing the preclinical evidences for using microRNA-based therapeutic strategies in this disease...
  30. pmc Waldenstrom macroglobulinemia
    Xavier Leleu
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Cancer Lett 270:95-107. 2008
    ..This report provides an update of the current preclinical studies and clinical efforts for the development of novel agents in the treatment of WM...
  31. doi request reprint The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia
    Anne Sophie Moreau
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, USA
    Br J Haematol 142:775-85. 2008
    ..Our studies therefore support our earlier observation of statin-mediated anti-WM activity and provide the framework for future clinical trials testing simvastatin in WM...
  32. doi request reprint LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas
    Yong Zhang
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 120:1678-86. 2012
    ..The results of the present study highlight the therapeutic potential of anti-miR-155-mediated inhibition of miR-155 in the treatment of WM...
  33. pmc Update on therapeutic options in Waldenström macroglobulinemia
    Xavier Leleu
    Kirsch Laboratory for Waldenström macroglobulinemia, Department of Medical Oncology, Dana Farber Cancer Institute DFCI and Harvard Medical School, Boston, MA, USA
    Eur J Haematol 82:1-12. 2009
    ..This report provides an update of the current preclinical studies and clinical efforts for the development of novel agents in the treatment of WM...
  34. pmc RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma
    Abdel Kareem Azab
    Medical Oncology, Dana Farber Cancer Institute, Massachusetts General Hospital, Harvard Medical School, 44 Binney Street, Boston, MA, USA
    Blood 114:619-29. 2009
    ..In conclusion, we characterized the role of RhoA and Rac1 GTPases in SDF1-induced adhesion, chemotaxis, and homing of MM cells to the BM, providing the framework for targeting RhoA and Rac1 GTPases as novel MM therapy...
  35. pmc Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia
    Jacob P Laubach
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Leuk Lymphoma 50:694-702. 2009
    ....
  36. pmc Novel Tumor Suppressor Function of Glucocorticoid-Induced TNF Receptor GITR in Multiple Myeloma
    Yang Liu
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 8:e66982. 2013
    ..These findings provide novel insights into the pivotal role of GITR in MM pathogenesis and disease progression...
  37. doi request reprint Epigenetics in Waldenström's macroglobulinemia
    Antonio Sacco
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Epigenomics 2:691-6. 2010
    ..In this study it has been demonstrated that WM patients present with a specific miRNA signature. Among deregulated miRNAs, miR-155 and miR-9* play a pivotal role in the pathogenesis of this disease...
  38. doi request reprint microRNA aberrations in Waldenström macroglobulinemia
    Antonio Sacco
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Clin Lymphoma Myeloma Leuk 13:205-7. 2013
    ....
  39. doi request reprint Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia
    Xavier Leleu
    Bing Center for Waldenstrom s Macroglobulinemia and Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 145:59-63. 2009
    ..These data depict for the first time a heterogeneous expression pattern of the genes involved in late differentiation process of plasma cells in patients with WM and propose a role of XBP1-ERN1alpha in WM pathogenesis...
  40. ncbi request reprint Targeted therapies in Waldenström macroglobulinemia
    Nicholas Burwick
    Dana Farber Cancer Institute, Department of Medical Oncology, 44 Binney Street, Boston, MA 02115, USA
    Curr Opin Investig Drugs 9:631-7. 2008
    ..In this review, the novel therapeutics that target these pathways are discussed...
  41. doi request reprint Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia
    Xavier Leleu
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School Boston, MA 02115, USA
    Leuk Lymphoma 49:1104-7. 2008
    ..This study demonstrates that sFLC is a new marker in WM disease. Further analysis is required to prospectively study the role of sFLC in monitoring response to therapy and as a prognostic marker in WM patients...
  42. pmc Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias
    Aldo M Roccaro
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    Biologics 2:419-31. 2008
    ....
  43. doi request reprint New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia
    Ghayas C Issa
    Medical Oncology, Pharmacy Department, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Hematol 18:260-5. 2011
    ..There have been recent significant advances in understanding the underlying pathogenesis of this disease, including genetic and epigenetic regulators of tumor progression...
  44. pmc SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma
    Hiroshi Yasui
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Mayer 557, 44 Binney St, Boston, MA 02115, USA
    Blood 106:706-12. 2005
    ..Our data, therefore, indicate that R-etodolac circumvents drug resistance in MM cells at clinically relevant concentrations, targets Mcl-1, and can be synergistically combined with Dex...
  45. doi request reprint Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia
    Anne Sophie Moreau
    Service des Maladies du Sang, CHRU, Lille, France
    Eur J Haematol 80:503-9. 2008
    ..Beta-2 microglobulin (b2m) is a major prognostic factor in WM and the heavy chain of HLA class I molecules, which are known to have immunosuppressive properties and have been implicated in the pathogeny of several malignancies...
  46. ncbi request reprint Development of vasculature targeting strategies for the treatment of chronic inflammatory diseases
    Girolamo Ranieri
    National Cancer Institute, Department of Clinical and Experimental Oncology, Bari, Italy
    Curr Drug Targets Inflamm Allergy 4:13-22. 2005
    ....
  47. ncbi request reprint Hematopoietic cancer and angiogenesis
    Domenico Ribatti
    Department of Human Anatomy and Histology, University of Bari Medical School, Bari, Italy
    Stem Cells Dev 13:484-95. 2004
    ....